Document is current
Any future updates will be listed below
-
Authors
Caraballo, Irene González https://orcid.org/0009-0000-3457-3091
Delgado, Bárbara Lobato
Zamorano, Magdalena Ruiz
Salgado, Mercedes
Pachón, Vanessa
Galán, Joaquina Martínez
Castellón, Victoria
Gardeazabal, Itziar
Ferrer, Ana
Pérez, Jaime Rubio
Escobar, Ignacio García
Fernández, Isaura
Quintanar, Teresa
Font, Carme
Alsar, Javier Soto
Morán, Laura Ortega
Fernández, José Manuel Soria
Martín, Andrés J. Muñoz
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 16 October 2025
First Online: 26 October 2025
Declarations
:
: Irene González Caraballo: Travel, accommodations, expenses: MSD, Rovi, Gilead, Rizmoic. Andrés Jesús Muñoz Martín: consultant or advisory role: GSK, Pfizer, BMS-Celgene, Sanofi, Astra-Zeneca, MSD, Lilly, Servier, Roche, Taiho, Leo Pharma, Regeneron. Research funding: Leo Pharma, Sanofi, BMS-Celgene. Speakers’ bureau: Rovi, Menarini, Stada, Medscape. Patents, royalties, other intellectual property: risk assessment model in venous thromboembolism in cancer patients. Liquid biopsy developed with laser technology. The rest of the authors declare no conflicts of interest for the present article.
